Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
Epratuzumab (anti-CD22) is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling, as well as depleting B cells moderately. The uncontrolled series discussed by Dörner and colleagues in this issue of Arthritis Rese...
Main Author: | Eisenberg, Robert |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2006
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526641/ |
Similar Items
-
ITU and the internet: déjà vu all over again
by: Colin, Blackman
Published: (2011) -
HEA Reauthorization: Deja Vu All Over Again?
Published: (1991) -
The renaissance of organic radical chemistry – deja vu all over again
by: Stephenson, Corey R J, et al.
Published: (2013) -
Not Deja Vu
by: Hafiz
Published: (2009) -
Déjà vu 4 U
by: Allan D., Spigelman
Published: (2008)